BTLA inhibitor (JS004)

Phase 2Small molecule

BTLA inhibitor (JS004) is one of 47 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

241 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 2

Camptosar

Pfizer

Phase 3

11 3

Keytruda

Merck & Co.

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

4 5

Eloxatin

Teva

Phase 3

4 6

Tecentriq

Roche

Phase 3

2 7

Opdivo

Bristol-Myers Squibb

Phase 3

2 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

9 9

Bayer Aspirin

Bayer

Phase 3

1 10

Taxotere

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT06588335

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT06588335·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BTLA inhibitor (JS004). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BTLA inhibitor (JS004) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BTLA inhibitor (JS004). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHenan Provincial People's Hospital

BTLA inhibitor (JS004)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News